Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-15 23:05 | 2025-09-12 | RAPP | Rapport Therapeutics, Inc. | PAUL STEVEN M | Director | Pharmaceutical Preparations | BUY | $24.65 | 41,666 | $1,027,113 | 41,666 | +100.0% |
| 2022-04-05 23:05 | 2022-04-01 | ALNY | Alnylam Pharmaceuticals Inc. | PAUL STEVEN M | Director | Pharmaceutical Preparations | OPT+S | $170.69 | 15,000 | $2,560,371 | 1,000 | -93.8% |
| 2021-08-19 02:43 | 2021-08-17 | KRTX | N/A | PAUL STEVEN M | Director, Officer; PRESIDENT & CEO | Other | BUY | $105.86 | 2,364 | $250,264 | 108,849 | +2.2% |
| 2020-12-23 00:02 | 2020-12-18 | ALNY | Alnylam Pharmaceuticals Inc. | PAUL STEVEN M | Director | Pharmaceutical Preparations | OPT+S | $140.00 | 15,000 | $2,100,000 | 1,000 | -93.8% |
| 2020-06-30 23:25 | 2020-06-29 | KRTX | N/A | PAUL STEVEN M | Director, Officer; PRESIDENT & CEO | Other | OPT+S | $103.50 | 292,207 | $30,243,425 | 106,485 | -73.3% |
| 2020-02-12 00:08 | 2020-02-10 | ALNY | Alnylam Pharmaceuticals Inc. | PAUL STEVEN M | Director | Pharmaceutical Preparations | OPT+S | $130.00 | 30,000 | $3,900,000 | 1,000 | -96.8% |
| 2019-07-02 03:26 | 2019-06-28 | KRTX | N/A | PAUL STEVEN M | Director, Officer; President & CEO | Other | BUY | $23.04 | 10,000 | $230,424 | 10,000 | +100.0% |
| 2019-03-22 23:22 | 2019-03-21 | SAGE | N/A | PAUL STEVEN M | Director | Other | SALE | $161.04 | 7,879 | $1,268,824 | 122,400 | -6.0% |
| 2019-03-21 03:47 | 2019-03-18 | SAGE | N/A | PAUL STEVEN M | Director | Other | SALE | $161.28 | 60,421 | $9,744,560 | 130,279 | -31.7% |
| 2019-03-06 00:18 | 2019-03-01 | SAGE | N/A | PAUL STEVEN M | Director | Other | SALE | $161.00 | 2,600 | $418,600 | 190,700 | -1.3% |
| 2019-02-28 01:48 | 2019-02-25 | SAGE | N/A | PAUL STEVEN M | Director | Other | SALE | $161.00 | 2,000 | $322,000 | 70,900 | -2.7% |
| 2019-02-20 15:55 | 2019-02-15 | SAGE | N/A | PAUL STEVEN M | Director | Other | SALE | $161.04 | 51,004 | $8,213,582 | 72,900 | -41.2% |
| 2018-03-09 00:02 | 2018-03-06 | SAGE | N/A | PAUL STEVEN M | Director | Other | SALE | $172.00 | 58,139 | $9,999,908 | 632,712 | -8.4% |
| 2016-01-16 01:01 | 2016-01-14 | VYGR | Voyager Therapeutics, Inc. | PAUL STEVEN M | Director, Officer; President and CEO | Biological Products, (No Diagnostic Substances) | BUY | $14.07 | 10,000 | $140,690 | 872,351 | +1.2% |
| 2015-09-02 22:43 | 2015-09-01 | SAGE | N/A | PAUL STEVEN M | Director | Other | SALE | $52.41 | 20,000 | $1,048,184 | 683,650 | -2.8% |
| 2015-08-04 18:32 | 2015-08-03 | SAGE | N/A | PAUL STEVEN M | Director | Other | SALE | $67.08 | 20,000 | $1,341,692 | 703,650 | -2.8% |
| 2015-07-02 21:10 | 2015-07-01 | SAGE | N/A | PAUL STEVEN M | Director | Other | SALE | $69.40 | 20,000 | $1,388,028 | 723,650 | -2.7% |
| 2015-06-03 01:11 | 2015-06-01 | SAGE | N/A | PAUL STEVEN M | Director | Other | SALE | $72.34 | 20,000 | $1,446,800 | 743,650 | -2.6% |
| 2015-05-05 21:29 | 2015-05-01 | BFAM | N/A | PAUL STEVEN M | Director | Other | SALE | $53.31 | 20,000 | $1,066,200 | 763,650 | -2.6% |
| 2015-04-02 18:28 | 2015-04-01 | SAGE | N/A | PAUL STEVEN M | Director | Other | SALE | $48.51 | 20,000 | $970,200 | 783,650 | -2.5% |
| 2015-01-29 01:10 | 2015-01-26 | ALNY | Alnylam Pharmaceuticals Inc. | PAUL STEVEN M | Director | Pharmaceutical Preparations | BUY | $95.00 | 1,000 | $95,000 | 1,000 | +100.0% |
| 2014-07-24 02:01 | 2014-07-23 | SAGE | N/A | PAUL STEVEN M | Director | Other | BUY | $18.00 | 10,000 | $180,000 | 803,650 | +1.3% |
| 2008-02-05 23:49 | 2008-02-04 | LLY | ELI LILLY & Co | PAUL STEVEN M | Officer; EVP, Science and Technology | Pharmaceutical Preparations | SALE | $51.60 | 19,822 | $1,022,881 | 50,300 | -28.3% |
| 2007-03-13 22:05 | 2007-03-12 | LLY | ELI LILLY & Co | PAUL STEVEN M | Officer; EVP, Science and Technology | Pharmaceutical Preparations | SALE | $52.39 | 7,289 | $381,871 | 1,070 | -87.2% |
| 2007-02-14 23:10 | 2007-02-12 | LLY | ELI LILLY & Co | PAUL STEVEN M | Officer; EVP, Science and Technology | Pharmaceutical Preparations | SALE | $54.38 | 7,290 | $396,430 | 8,359 | -46.6% |
| 2007-02-12 18:39 | 2007-02-08 | LLY | ELI LILLY & Co | PAUL STEVEN M | Officer; EVP, Science and Technology | Pharmaceutical Preparations | SALE | $54.32 | 10,092 | $548,234 | 54,619 | -15.6% |
| 2006-10-24 18:37 | 2006-10-20 | LLY | ELI LILLY & Co | PAUL STEVEN M | Officer; EVP, Science and Technology | Pharmaceutical Preparations | SALE | $56.91 | 4,836 | $275,217 | 1,070 | -81.9% |
| 2006-04-26 20:28 | 2006-04-25 | LLY | ELI LILLY & Co | PAUL STEVEN M | Officer; EVP, Science and Technology | Pharmaceutical Preparations | SALE | $52.06 | 25,000 | $1,301,508 | 39,656 | -38.7% |
| 2006-04-25 22:51 | 2006-04-21 | LLY | ELI LILLY & Co | PAUL STEVEN M | Officer; EVP, Science and Technology | Pharmaceutical Preparations | SALE | $52.80 | 25,000 | $1,320,000 | 64,656 | -27.9% |
| 2006-02-03 22:42 | 2006-02-02 | LLY | ELI LILLY & Co | PAUL STEVEN M | Officer; EVP, Science and Technology | Pharmaceutical Preparations | SALE | $57.00 | 6,201 | $353,457 | 89,656 | -6.5% |
| 2003-08-05 22:45 | 2003-08-05 | LLY | ELI LILLY & Co | PAUL STEVEN M | Officer; EVP, Science and Technology | Pharmaceutical Preparations | SALE | $64.87 | 10,000 | $648,716 | 28,877 | -25.7% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.